The efficacy of this agent in preclinical models of both CCNE1-amplified and CDK4/6i–resistant cancers was encouraging and supported the rationale for targeting CDK2 in cancer, but its clinical development has been discontinued (16). This evidence concerns the gene CDK4 and cancer.